Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | FOS | P01100 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | JUN | P05412 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044667 | 0.87 | LMNA (0.40) | CA2PTGS2HTR2AALOX15ALOX12 | |
| SCHEMBL3043068 | 0.81 | CA2 (0.35) | CA2PTGS2HTR2AALOX15ALOX12 | |
| SCHEMBL3026929 | 0.81 | ALDH1A1 (0.34) | ALDH1A1CA2PTGS2SIGMAR1ALOX15 | |
| SCHEMBL1613836 | 0.80 | MAPT (0.37) | CA2PTGS2HTR2AFOSTTR | |
| SCHEMBL1023208 | 0.74 | PTGS2 (0.41) | ALDH1A1SMN1; SMN2CA2PTGS2HTR2A | |
| SCHEMBL21519802 | 0.73 | SMPD1 (0.39) | PTGS2 | |
| SCHEMBL3037185 | 0.72 | PTGS2 (0.40) | ALDH1A1CA2PTGS2HTR2A | |
| SCHEMBL21519740 | 0.71 | PTGS2 (0.34) | SMN1; SMN2CA2PTGS2MEN1KMT2A | |
| SCHEMBL21540549 | 0.70 | L3MBTL1 (0.35) | SMN1; SMN2CA2PTGS2MEN1KMT2A | |
| SCHEMBL30677952 | 0.70 | L3MBTL1 (0.35) | SMN1; SMN2CA2PTGS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100217001-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100217001-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100217001-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2202233-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202233-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217001-A1 | METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE | CYP3A4, CYP4B1, CYP51A1 | ALDH1A1 257/4885SMN1; SMN2 3795/4885CA2 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.